tbuckley/cabot-search huggingface dataset:
Unsettled Weather
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2015)

Ad Libitum15 September 2015Unsettled WeatherJack Coulehan, MD, MPHJack Coulehan, MD, MPHFrom Setauket, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M15-1164 Audio Reading - “Unsettled Weather” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Unsettled Weather," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The hostile wind is at its worst tonight.Rain is fierce and thunder jars cement.Upstairs, a woman who should have diedlast week—she did, but medics came—slips backward and sheds an interior layer,like the beach of a barrier islandwhen a hurricane carries it under.Above the entry wound, my patient's cheekis swollen purple, her zygomatic archturned citrus tense. A sister from Wyandanchrests her fingers on an arm that's overripe.No, we can never give up. Scars constrictthe patient's lungs from too much care.The only secret that remains is her.Jack Coulehan, MD, MPHSetauket, New York Author, Article, and Disclosure InformationAffiliations: From Setauket, New York.Current Author Address: Jack Coulehan, MD, MPH; e-mail, John.[email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Unsettled Weather” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "Unsettled Weather," by J. Coulehan. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 September 2015Volume 163, Issue 6Page: 471KeywordsLungsScars ePublished: 15 September 2015 Issue Published: 15 September 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Gastric analysis
Authors: H. L. Segal
Journal: JAMA (1966)

The renaissance of interest in the gastric mucosa has produced both a more exact knowledge of the physiology of gastric secretion and new tools for clinical application. Recent investigations have resulted in the demonstration of four distinct human pepsinogens and pepsins<sup>1</sup>and the isolation of two pure gastrins.<sup>2</sup>Tubeless tools are available to determine the capability of gastric mucosa to secrete acid, pepsinogens, and intrinsic tumor. Intubation techniques allow estimation of parietal cell population (maximum acid output)<sup>3</sup>and determination of the percentage of the parietal cells secreting under basal conditions and after vagotomy. Assay methods<sup>4,5</sup>have been developed to measure intrinsic factor in gastric juice aspirate. All this signifies that gastric analysis is not only a test to determine the acidity of aspirated gastric juice, but also a means to measure the basal and maximum acid outputs and the capability of the gastric mucosa to secrete
Note from the editors: Consensus paper on MLVA development, validation, nomenclature and quality control – an important step forward for molecular typing-based surveillance and outbreak investigation
Authors: None Eurosurveillance editorial team
Journal: Eurosurveillance (2013)

Preview this article: Note from the editors: Consensus paper on MLVA development, validation, nomenclature and quality control – an important step forward for molecular typing-based surveillance and outbreak investigation, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/18/35/art20570-en-1.gif
Epidemiology and prevention of hepatitis A in travelers
Authors: R. Steffen
Journal: JAMA (1994)

<h3>Objective.</h3> —To assess the risk of hepatitis A in international travelers and to recommend preventive measures. <h3>Data Sources.</h3> —<i>Index Medicus</i>, 1974 through 1983; MEDLINE, 1984 through 1993; and unpublished data of the Centers for Disease Control and Prevention. <h3>Study Selection.</h3> —Review of all retrospective and cohort studies on hepatitis A and other vaccine-preventable diseases in travelers, of seroepidemiologic surveys of hepatitis A virus (HAV) antibodies in travelers, of data on the various hepatitis A vaccines, of economic analyses, and of recommendations of recognized organizations. <h3>Data Extraction.</h3> —Independent analysis by multiple observers. <h3>Data Synthesis.</h3> —The incidence rate for unprotected travelers, including those staying in luxury hotels, is estimated to be three per 1000 travelers per month of stay in a developing country. Persons eating and drinking under poor hygienic conditions have a rate of 20/1000 per month. This makes hepatitis A the most frequent infection in travelers that may be prevented by immunization. In many industrialized countries persons born after 1945 have an HAV antibody seroprevalence (immunity) of less than 20%. New inactivated HAV vaccines induce protective antibodies in more than 95% of recipients and offer protection estimated to last for 10 years or more, whereas protection by immune globulin lasts only 3 to 5 months. <h3>Conclusions.</h3> —Hepatitis A vaccine, or immune globulin where HAV vaccine is not available, is recommended for all nonimmune travelers visiting developing countries. Prescreening for antibodies to HAV in travelers living in countries with low prevalence is usually not necessary in persons born after 1945. (<i>JAMA</i>. 1994;272:885-889)
Preventing unsafe abortions through task shifting and sharing
Authors: None The Lancet
Journal: The Lancet (2015)

Worldwide, 22 million unsafe abortions are done each year, which contributes substantially to the global burden of maternal mortality and morbidity. Most unsafe abortions occur in low-income countries, especially in Africa, in rural and remote areas, where the shortage of trained health-care providers is greatest and maternal mortality and morbidity is highest. The global deficit of skilled health-care professionals—midwives, nurses, and physicians—will be 12·9 million by 2035.
THE EASTER SEAL APPEAL
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study
Authors: D. V. Jackson
Journal: JAMA (1977)

Twenty-nine patients with small cell carcinoma of the lung and without evidence of brain metastasis were randomized into two treatment groups consisting of 14 patients who received prophylactic cranial irradiation (PCI) and 15 who received none (non-PCI). All patients were treated with irradiation of the primary lesion and concomitant chemotherapy. The response rate and median survival of the two groups were not significantly different: 93% and 7.2 months in the non-PCI; 86% and 9.8 months in the PCI;<i>P</i>≥.05. Brain metastasis occurred in 0/14 patients in the PCI and 4/15 in the non-PCI (<i>P</i>≤.05) and was the cause of major neurologic disability in each. Although PCI did not improve response rate or survival, brain metastasis with its attendant neurologic complications was effectively prevented. (<i>JAMA</i>237:2730-2733, 1977)
West Nile Virus Activity—United States, September 26–October 2, 2002, and Investigations of West Nile Virus Infections in Recipients of Blood Transfusion and Organ Transplantation
Journal: JAMA (2002)

This report summarizes West Nile virus (WNV) surveillance data reported to CDC through ArboNET and by states and other jurisdictions as of 7 a.m. Mountain Daylight Time, October 2, 2002, and updates preliminary demographic and clinical information on cases of WNV infections inrecipients of blood transfusion and organ transplantation reported to CDC during August 28-October 2, 2002.
Counseling and Testing Intravenous-Drug Users for HIV Infection — Boston
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1
Authors: M.L. Friedlander, K. Moore, N. Colombo, G. Scambia, B-G. Kim, A. Oaknin, A. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, S. Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, E. Holmes, E.S. Lowe, P. Disilvestro
Journal: Annals of Oncology (2020)
Tumor-Specific Immune Mechanisms
Authors: Richard T. Smith
Journal: New England Journal of Medicine (1968)

Summary of Immunologic Surveillance and Escape MechanismsIn commenting upon possible evolutionary or selective pressures that resulted in transplantation immunity in mammals, Thomas98 proposed, in 1958, that this mechanism best met the need for surveillance and destruction of somatically altered cells that had escaped from normal metazoan growth controls. Establishment that neoplastic transformation of cells is inevitably associated with a newly acquired antigenicity of the evolving clone provided a key element previously missing. Support for this hypothesis is that the rejection of autochthonous or syngeneic MCA tumors may occur as a result of direct activity of the lymphoreticular system. Moreover, . . .
THE HISTORY OF THE MICROBE OF EPIDEMIC DYSENTERY.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3181: A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures
Authors: Brock Binkowski, Aileen Paguio, Christopher Eggers, Braeden Butler, Michael Beck, Frank Fan
Journal: Cancer Research (2019)

Abstract Efforts to develop and commercialize T cell immunotherapies would benefit from sensitive and easy-to-use assays to monitor target cell killing. We have developed an approach to selectively measure the death of target cells mediated by CAR/TCR-T cells or other types of effector cells. The method relies on the release of a HiBiT-tagged protein from target cells following cell lysis. Once released, HiBiT, an 11 a.a. peptide tag, binds to cell-impermeable Large BiT (LgBiT), a 17.6 kDa protein, to reconstitute NanoBiT Luciferase. In the presence of furimazine substrate, the luminescent signal is proportional to the amount of target cell killing, and cell lysis can be quantified at a single time point using Maximum Release and Spontaneous Release controls. The assay is compatible with a wide range of target cells per well (e.g. 100-500,000 cells/well), and low levels of Spontaneous Release allow the sensitive detection of low levels of target cell lysis (e.g. 1-5%). Using a modified format, target cell killing can be measured continuously in a bench-top luminometer for 24 hours or more. We demonstrate these approaches using commercially available CAR-T cells and target cells stably expressing a HiBiT-tagged protein via random integration of plasmid DNA or viral transduction. We also demonstrate the use of a thaw-and-use format to facilitate MOA-based lot release assays. The approach provides simple, non-radioactive assay formats for selectively monitoring target cell killing in mixed culture experiments. Citation Format: Brock Binkowski, Aileen Paguio, Christopher Eggers, Braeden Butler, Michael Beck, Frank Fan. A novel, bioluminescent assay for the selective detection of target cell killing in mixed cultures [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3181.
The cost of not doing medical research
Authors: W. C. Gibson
Journal: JAMA (1980)

At a time when governmental expenditures on medical research are being questioned by treasury boards, it seems wise to review historical examples of profitable investment in such research. Differentiation of medical research from medical technology is essential in this confrontation. Continuity of merited research support is a key factor in attracting inquisitive and gifted minds to this area of medical science. Medical research should be seen as a social investment and not as a charity. (<i>JAMA</i>244:1817-1819, 1980)
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).
Authors: Mafalda Oliveira, Cristina Saura, Antonio Gonzalez-Martin, Jay C. Andersen, Julie Gottlieb Fisher, Isabel Calvo, Eva Ciruelos, Miquel Gil, Lorena De La Pena, Marta Llobet-Canela, YounJeong Choi, Shidong Jia, Sreenivasu Yalamanchili, Stina Mui Singel, Premal H. Patel, Jose Baselga, Steven J. Isakoff
Journal: Journal of Clinical Oncology (2015)

TPS1112 Background: TNBC often exhibits activation of PI3K/Akt signaling, associated with loss of PTEN expression, low INPP4B expression, and/or increased AKT3 amplification. Inhibition of the PI3K/Akt pathway in diverse cancers leads to radiosensitization and/or chemosensitization. Ipat is an oral, potent ATP-competitive small molecule inhibitor of all three isoforms of Akt. The combination of ipat with taxanes in preclinical models resulted in enhanced efficacy relative to either ipat or chemotherapy alone. In a Phase Ib clinical study, the combination of Ipat with diverse chemotherapy regimens was well-tolerated and resulted in RECIST responses, particularly pts with tumors having PI3K/Akt activation. Methods: FAIRLANE is a randomized, double-blind, placebo-controlled, multicenter, neoadjuvant Phase II study designed to estimate the efficacy of ipat combined with pac versus placebo combined with pac in women with Stage Ia - IIIa TNBC. Approximately 150 patients (Pts) will be enrolled, randomized in a 1:1 ratio, and stratified by PTEN status, node involvement, and tumor size. Pts will receive 3 cycles of Ipat or placebo 400 mg orally once daily on Days 1 to 21 of each 28-day cycle, along with pac 80 mg/m2 every 7 days for a total of 12 doses. All patients will undergo pretreatment and Day 8 tumor tissue acquisition to evaluate pathway biomarkers. Following three cycles of treatment, patients will undergo surgery. The primary efficacy endpoint, pCR within the breast and axilla (ypT0/Tis ypN0) in all patients and in patients with PTEN-low tumors, will be assessed by local pathology evaluation following completion of neoadjuvant therapy and surgery. Additional endpoints include objective response rate, safety, BCS rate, pharmacokinetics, and pathway biomarkers. Following surgical resection of primary tumor, patients are expected to continue post-operative treatment with a standard adjuvant chemotherapy regimen at physician’s discretion. The study is open for accrual. Clinical trial information: NCT02301988.
ANTISTREPTOCOCCUS SERUM IN SCARLET FEVER.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Racial/Ethnic and Socioeconomic Disparities in Multiple Risk Factors for Heart Disease and Stroke—United States, 2003
Journal: JAMA (2005)

Heart disease and stroke are the first and third leading causes of death, respectively, in the United States. Certain modifiable risk factors, including high blood pressure, high cholesterol, diabetes, tobacco use, obesity, and lack of exercise, are the main targets for primary and secondary prevention of heart disease and stroke. A substantial proportion of the population has multiple risk factors, increasing their likelihood of cardiovascular disease. To assess the prevalence of multiple risk factors for heart disease and stroke and to identify disparities in risk status among population subgroups, CDC analyzed data from the 2003 Behavioral Risk Factor Surveillance System (BRFSS) survey. This report summarizes the results of that analysis, which indicated that approximately 37% of the survey population had two or more risk factors for heart disease and stroke and that considerable disparities in risk factors existed among socioeconomic groups and racial/ethnic populations. To decrease morbidity and mortality from heart disease and stroke, public health programs should improve identification of persons with multiple risk factors and focus interventions on those populations disproportionately affected.
TUBERCULIN IN TREATMENT OF NON -TUBERCULOUS AFFECTIONS.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer of the Uterus, Its Pathology, Symptomatology, and Treatment; also the Pathology of Diseases of the Endometrium.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal